Pharmacokinetics and 180‐day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2–5 years
This study characterizes the PK of diazepam in patients 2-5 years of age and reports a safety profile consistent with older patients. Results demonstrate that the diazepam nasal spray drug-device combination is appropriate for drug delivery and absorption in these patients.
Authors
- James W. Wheless (ORCID: https://orcid.org/0000-0002-4735-3431)
- Leock Y. Ngo (ORCID: https://orcid.org/0000-0002-8184-1367)
- Enrique J. Carrazana (ORCID: https://orcid.org/0000-0001-8788-0722)
- Eric Segal (ORCID: https://orcid.org/0000-0002-9986-6394)
- Adrián L. Rabinowicz (ORCID: https://orcid.org/0000-0003-1299-0606)
- Evelyn K. Shih (ORCID: https://orcid.org/0000-0002-8455-0231)
- Muhammad Zeeshan Zafar (ORCID: https://orcid.org/0009-0007-1677-3955)
Institutions
- University of Hawaiʻi at Mānoa (US)
- Hackensack University Medical Center (US)
- University of Tennessee Health Science Center (US)
- Duke University (US)
- NorthEast Regional Epilepsy Group (US)
- Neurelis (United States) (US)
- Hackensack Meridian Health (US)
- Le Bonheur Children's Hospital (US)
- Florida Atlantic University (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1111/epi.18473
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47